Reprise: Gemtuzumab ozogamicin for older patients with acute myeloid leukemia

Journal of Clinical Oncology

Volumn 30, Issue 32, 2012, Pages 3905-3906

  Neuberg, Donna S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADULT; AGED; CANCER CHEMOTHERAPY; DRUG WITHDRAWAL; EDITORIAL; GERIATRIC PATIENT; HUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 84869386258     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.6592     Document Type: Editorial

References (5)

1. Burnett AK, Russell N, Hills RK, et al: The addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 30:3924-3931, 2012
2. US Food and Drug Administration: Gemtuzumab ozogamicin. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/ CDER/ucm216790.htm
3. US Food and Drug Administration: FDA: Pfizer voluntarily withdraws cancer treatment Mylotarg from US market. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2010/ucm216448.htm
4. Petersdorf S, Kopecky K, Stuart RK, et al: Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy followed by a second randomization to postconsolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 114:790, 2009
5. Castaigne S, Pautas C, Terré C, et al: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomized, open-label, phase 3 study. Lancet 379:1508-1516, 2012